Omsætningsudviklingen for forretningsområderne Urologi og Kontinens vil fremadrettet blive præsenteret enkeltvis og ikke som et samlet forretningsområde.
Se vedlagte pdf.
Recommended Reading
-
Coloplast has been informed that the Danish Financial Supervisory Authority (FSA) has today announced that it has notified Niels Peter Louis-Hansen that it has granted an exemption from the obligation...
Read More -
Interim financial results, 9M 2025/261 October 2025 - 30 June 2026 Coloplast delivered Q3 organic growth of 6% and 5% EBIT growth1 in constant currencies. Strong quarter in both Chronic Care ex....
Read More